CYTH - Cyclo therapeutics to join Russell 2000 Index

Cyclo Therapeutics (CYTH) will join the Russell 2000 Index following the annual reconstitution of the index, effective June 25 after the close of the U.S. equity markets. "Inclusion in the Russell 2000 Index, which is widely used as a performance benchmark, brings added value, market access and an opportunity to raise awareness more broadly as we work to execute our pivotal phase 3 study in Niemann-Pick Disease Type C and advance towards a phase 2 study with our Alzheimer's Disease asset," said Cyclo CEO Scott Fine.CYTH -0.83% premarket to $10.69Source: Press Release

For further details see:

Cyclo therapeutics to join Russell 2000 Index